Immutep granted a new European patent

Company News

by Rachael Jones

Biotech company Immutep (ASX:IMM), specialises in immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce the grant of a new patent by the European Patent Office.

The patent is entitled “Combined Preparations for the Treatment of Cancer”

It protects Immutep’s intellectual property relating to combined therapeutic preparations comprising its lead active immunotherapy candidate efti-lagimod alpha (“efti” or “IMP321”) and a chemotherapy agent.

The patent expiry date is 19 December 2034.

Shares in Immutep (ASX:IMM)

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.